"We performed testing of the new OncoScan® FFPE Assay Kit at ARUP and were able to detect FISH-confirmed aberrations in several key cancer genes including ERBB2, MDM2, EGFR, and MYC suggesting that OncoScan FFPE Assay Kit can be considered a viable, higher resolution and higher specificity alternative to FISH testing for confirmation of cancer gene aberrations in solid tumor tissue. Because OncoScan FFPE Assay Kit has whole-genome resolution, we also obtained valuable incremental copy number aberrations in these samples."
Sarah South, PhD, Medical Director, Cytogenetics, Genomic Microarray and Genetic Processing Laboratories, ARUP Laboratories
"We believe that the OncoScan assay is a robust platform for the rapid discovery and validation of novel prognostic copy number signatures that may also be useful in a clinical setting for the detection of specific gains in tumors as markers for patient stratification."
Professor Torsten Pietsch, MD, PhD, Institute of Neuropathology, University of Bonn, Germany